|
Randomized phase III trial of adjuvant pazopanib versus placebo after nephrectomy in patients with locally advanced renal cell carcinoma (RCC) (PROTECT). |
|
|
Consulting or Advisory Role - Eisai; Exelixis; Novartis; Pfizer |
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
Consulting or Advisory Role - Exelixis; Novartis; Pfizer |
|
|
Research Funding - GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst) |
|
|
Honoraria - GlaxoSmithKline; Ipsen; Novartis; Pfizer |
Consulting or Advisory Role - Bristol-Myers Squibb; Ipsen; Novartis; Pfizer |
Speakers' Bureau - Novartis; Pfizer |
Research Funding - GlaxoSmithKline; Ipsen; Novartis; Roche |
|
|
No Relationships to Disclose |
|
|
Employment - Omsk Clinical Oncological Dispensary |
Leadership - Omsk Clinical Oncological Dispensary |
Research Funding - Omsk Clinical Oncological Dispensary |
Patents, Royalties, Other Intellectual Property - Omsk Clincal Oncological Dispensary |
Travel, Accommodations, Expenses - Omsk Clinical Oncological Dispensary |
|
|
Honoraria - Astellas Pharma; Novartis; Pfizer |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Eisai |
Research Funding - Exelixis; Janssen; Novartis; Pfizer |
|
|
Honoraria - Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen; Lilly; Merck; Merck Sharp & Dohme; Novartis; Pfizer; Roche |
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck; Novartis; Roche |
|
|
Consulting or Advisory Role - Pfizer |
Research Funding - Bristol-Myers Squibb (Inst); Pfizer (Inst); Roche/Genentech (Inst) |
Travel, Accommodations, Expenses - Pfizer |
|
|
Honoraria - NCCN; UpToDate |
Consulting or Advisory Role - alligent; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Eisai; Exelixis; Foundation Medicine; GlaxoSmithKline; Merck; Novartis; Peloton Therapeutics; Pfizer; Prometheus; Roche/Genentech |
Research Funding - Agensys (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); TRACON Pharma (Inst) |
Travel, Accommodations, Expenses - advisory boards/consultancy |
|
|
Consulting or Advisory Role - Pfizer |
Speakers' Bureau - Bristol-Myers Squibb |
Travel, Accommodations, Expenses - Merck Sharp & Dohme |
|
|
Research Funding - Bristol-Myers Squibb; Merck; Novartis; Pfizer; Roche |
|
|
No Relationships to Disclose |
|
|
Honoraria - Ferring; Merck; Novartis; Sanofi |
Consulting or Advisory Role - Astellas Pharma; Bayer; Janssen; Pfizer; Roche |
|
|
Honoraria - Alere; Ipsen; Janssen |
Consulting or Advisory Role - Astellas Pharma; Ipsen; Karl Storz; Rodr |
Research Funding - Amgen; Bayer; Ipsen; Janssen; Roche |
Travel, Accommodations, Expenses - Amgen; European Association of Urology; Ipsen; Novartis; Roche |
|
|
Employment - Novartis; Novartis (I) |
|
|
Research Funding - Novartis (Inst) |
Travel, Accommodations, Expenses - Novartis |
|
|
Stock and Other Ownership Interests - AstraZeneca; Bayer; Bristol-Myers Squibb |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Novartis; Pfizer; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |